1. Home
  2. STIM vs ZNTL Comparison

STIM vs ZNTL Comparison

Compare STIM & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neuronetics Inc.

STIM

Neuronetics Inc.

N/A

Current Price

$1.32

Market Cap

105.5M

Sector

Health Care

ML Signal

N/A

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

N/A

Current Price

$2.50

Market Cap

156.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
STIM
ZNTL
Founded
2003
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
105.5M
156.7M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
STIM
ZNTL
Price
$1.32
$2.50
Analyst Decision
Strong Buy
Buy
Analyst Count
2
5
Target Price
$7.00
$6.60
AVG Volume (30 Days)
2.2M
578.2K
Earning Date
05-01-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
47.87
EPS
N/A
N/A
Revenue
$52,776,000.00
$67,425,000.00
Revenue This Year
$101.67
N/A
Revenue Next Year
$10.87
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.17
$1.01
52 Week High
$5.34
$3.95

Technical Indicators

Market Signals
Indicator
STIM
ZNTL
Relative Strength Index (RSI) 42.63 52.16
Support Level $1.24 $1.27
Resistance Level $2.13 $2.69
Average True Range (ATR) 0.11 0.19
MACD 0.01 -0.01
Stochastic Oscillator 46.77 66.95

Price Performance

Historical Comparison
STIM
ZNTL

About STIM Neuronetics Inc.

Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Share on Social Networks: